CNN

U.S. patients try stem cell therapies abroad

But the family is convinced of their next step -- taking Sierra on an arduous trip to southern China, where they believe the little girl will be injected six times with stem cells during a 34-day stay ...

Final wish denied as Colorado ALS patient's access to experimental drug stalls

At 71 years old, facing a terminal diagnosis, Colorado resident Tom Pringle has one more thing he wants to do before he dies: ...

New ALS treatment target identified: STAUFEN-1 protein reduction protects brain cells from death

University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein ...
Jackson Hole Community Radio - KHOL 89.1 FM

Jackson-based lab is developing a blood test to help diagnose ALS

According to Brain Chemistry Labs, the in-the-works test can identify an ALS patient with 97% accuracy. The next step is to ...

VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS

VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S.

Moose Jaw police say they've had ‘no previous complaints’ about ALS health centre. They're mistaken

Two people who filed formal complaints about the Dr. Goodenowe Restorative Health Center in Moose Jaw, Sask. are asking why ...
The Fresh Toast

The Latest On Medical Cannabis and ALS

The Fresh Toast - the latest on medical cannabis and ALS explores symptoms, research, patient relief options, and emerging ...
Times Argus

QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener

QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...
Morningstar

QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener

QurAlis intends to advance QRL-101 into Phase 2 proof-of-concept clinical trials as a potentially best-in-class treatment for both DEE and ALS QurAlis Corporation (“QurAlis”), a clinical-stage ...
WHDH

Dozens ‘Plunge for Pete’ in Gloucester to raise money for ALS patients, research

GLOUCESTER , MASS. (WHDH) - The annual Plunge for Pete, a mass dip into the icy Atlantic to raise money for ALS patients, drew dozens of people to Gloucester on Saturday in the hopes of raising ...
MedPage Today

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from ...

New drug may slow progression of ALS in small group of patients, study finds

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...